TORONTO, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI) (OTCQB: CNVIF) (“Conavi” or the “Company”), a commercial-stage medical device company focused on designing, manufacturing, and marketing imaging technologies to guide minimally invasive cardiovascular procedures, today announced that it will be presenting at the Planet MicroCap Showcase: TORONTO 2025 in partnership with MicroCapClub on Wednesday, October 22, 2025 at 9:30 AM (EST) at the Arcadian Loft in Downtown Toronto. Tom Looby, ...

Core Insights - Conavi Medical Corp. reported its financial results for the fiscal quarter ended June 30, 2025, highlighting significant developments in its product pipeline and financial position [1][11]. Business Highlights - The company completed successful validation testing of its next-generation Novasight™ system with leading interventional cardiologists, confirming its competitiveness with existing IVUS and OCT solutions [2][3]. - A $20 million financing round completed in April 2025 strengthens the company's balance sheet, providing resources for regulatory submission and production transition [6][8]. Regulatory and Production Milestones - Conavi is on track to submit its 510(k) application to the U.S. FDA in Q3 2025, which is crucial for its planned U.S. launch in the first half of 2026 [4][10]. - The transition of the Novasight system from development to manufacturing is underway, expected to align with the U.S. launch timeline [4]. Financial Performance - For Q3 FY 2025, the company recorded revenue of CAD 63,000, a decrease from CAD 401,000 in the same period the previous year [11]. - Operating expenses were CAD 4.7 million, down from CAD 8.8 million year-over-year, leading to a reduced operating loss of CAD 4.6 million compared to CAD 8.9 million in Q3 FY 2024 [12]. - The net loss for Q3 FY 2025 was CAD 3.6 million, or CAD 0.05 per share, significantly improved from a net loss of CAD 13.0 million, or CAD 2.12 per share, in the prior year [13]. Market Context - A publication in the Journal of the American College of Cardiology emphasizes the growing importance of intravascular imaging in treating complex coronary artery disease, indicating a favorable market environment for Conavi's hybrid imaging technology [2][5].

Core Insights - Conavi Medical Corp. is hosting a live webinar to discuss its innovative imaging technology for minimally invasive cardiovascular procedures [1][2] - The CEO, Tom Looby, will present the company's market-leading Novasight Hybrid™ System, which combines intravascular ultrasound (IVUS) and optical coherence tomography (OCT) [1][3] - The Novasight Hybrid System has received regulatory approvals from the U.S. FDA, Health Canada, China's National Medical Products Administration, and Japan's Ministry of Health, Labor and Welfare [3] Event Details - The webinar is scheduled for June 24th at 4 PM ET / 1 PM PT, and will include a Q&A session for attendees [2] - A recording of the event will be available for those unable to attend live [2] - Radius Research, part of Market Radius Capital, Inc., will host the event, providing individual investors with access to in-depth discussions [2] Company Overview - Conavi Medical focuses on designing, manufacturing, and marketing imaging technologies specifically for cardiovascular procedures [3] - The Novasight Hybrid™ System is the first of its kind to enable simultaneous imaging of coronary arteries using both IVUS and OCT [3]

The remaining Stock Options were granted to other employees and consultants. The Company also announced minor changes to the composition of its Audit Committee, with Board Chair Aaron Davidson having stepped down from the Audit Committee and independent directors Susan Allen, Cathy Steiner and Robert Mitchell continuing to serve. About Conavi Medical Conavi Medical is focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures. Its pat ...

Core Insights - Conavi Medical's Novasight Hybrid™ System has been awarded "Product Innovation of the Year" at the 2025 Minnesota Manufacturing Awards, highlighting its significant advancement in intracoronary imaging technology [1][2][3] Company Overview - Conavi Medical is a medical device company focused on designing, manufacturing, and marketing imaging technologies for minimally invasive cardiovascular procedures [4] - The Novasight Hybrid™ System is the first device to integrate intravascular ultrasound (IVUS) and optical coherence tomography (OCT) for simultaneous imaging of coronary arteries, providing comprehensive insights for interventional cardiologists [2][4] Industry Recognition - The Minnesota Manufacturing Awards celebrate innovation, leadership, and growth within Minnesota's manufacturing sector, with Conavi Medical and Novasight being featured in a special publication by the Minneapolis/St. Paul Business Journal [3]